Join Here   |   Log In

CYP1A2 Gene: Fast or Slow Caffeine Metabolizer and More

Key Takeaways:

  • CYP1A2 is a phase I detoxification enzyme that breaks down caffeine as well as several important toxins, such as aflatoxin B1 from mold.
  • CYP1A2 also plays a role in estrogen metabolism and melatonin metabolism.
  • Common genetic variants in CYP1A2 influence whether you are a fast or slow metabolizer of caffeine and other CYP1A2 substrates.

This article is part of the Detoxification and Medication Genetic Lifehacks Hub.

Members will see their genotype report below, plus additional solutions in the Lifehacks section. Join today 

CYP1A2 Function: Caffeine Metabolism and More

The CYP family of genes codes for enzymes that are used by the body to break down and get rid of things like toxins, pollutants, drugs, and substances our body naturally makes. Genetic variants in the CYP genes impact how quickly we break down various drugs and other toxins, and understanding your genetic polymorphisms (variants) can shed light on how your body reacts to things.

The function of the CYP1A2 enzyme is to break down certain substances to make them more easily excreted from the body.

Specifically, the CYP1A2 enzyme is involved in the metabolism (breakdown) of caffeine and aflatoxin B1, a mold toxin found on grains and peanuts.[ref]

Related article: Mycotoxins, mold, and detoxification

Endogenous substances metabolized by CYP1A2:

In addition, CYP1A2 also breaks down endogenous substances in the body, including:

  • Melatonin
  • Bilirubin
  • Estrogens

Related article: Estrogen metabolism (including role of CYP1A2) and Gilbert’s Syndrome

Medications metabolized by CYP1A2:

CYP1A2 breaks down several prescription medications (substrates). Common medications for which CYP1A2 is involved in metabolism include:[ref][ref][ref]

  • clozapine
  • olanzapine
  • theophylline
  • tizanidine
  • paroxetine
  • escitalopram

However, many medications are metabolized by multiple CYP enzymes, so genetic variants in CYP1A2 alone may not accurately predict your response to a medication.

Substrates, Inducers, and Inhibitors – what does this mean?

  • When it comes to the CYP450 enzymes, substrates are the substances that the enzyme acts on to break it down. Caffeine would be an example of a substrate of CYP1A2.
  • Other substances, called inducers, cause the body to produce more of the enzyme.  Cigarette smoke is an example of an inducer.
  • Inhibitors are substances that inhibit the enzyme from being produced or from working normally.

Genetic variants interact with medications as well as other substances (such as caffeine) that are metabolized by the same enzyme.[ref] For example, someone with a slow CYP1A2 genotype may find that taking an inhibitor of CYP1A2 at the same time as drinking a caffeinated beverage causes the caffeine to remain in their system longer.

There is a list of drugs, inducers, and inhibitors of CYP1A2 on Wikipedia.

What speeds up CYP1A2 (inducers)?

The polycyclic aromatic hydrocarbons (PAHs) found in cigarette smoke upregulate or increase the expression of CYP1A2. PAHs are also produced in incomplete combustion, such as wood fires, vehicle exhaust, or coal burning.

The largest source of PAHs is due to cigarette smoke or heavy marijuana smoke.[ref]

  • Cigarette smoking may cause a faster clearance of some drugs that are metabolized through CYP1A2.
  • Smoking may also make you clear out caffeine faster.

For example, smokers who take duloxetine may end up with lower levels of the drug in their system because cigarette smoke speeds up CYP1A2.[ref]

CYP1A2 is also induced (activated) by cruciferous vegetables such as cabbage, cauliflower, and broccoli.[ref] This is one reason why cruciferous vegetables may be beneficial for clearing out estrogen metabolites, through inducing more CYP1A2.

Related article: Estrogen metabolism

Phenytoin, an antiseizure medication, is also a moderate inducer of CYP1A2.[ref]

Which supplements and drugs inhibit CYP1A2?

CYP1A2 is inhibited, at least partially, by the following natural supplements:[ref][ref][ref]

  • Curcumin and turmeric
  • Peppermint
  • Chamomile
  • Dandelion
  • St. John’s wort

Related articles: Curcumin Supplements: Decreasing Inflammation & Nootropics and Genetics: Smart Drugs and Your Genes

Medications can also inhibit CYP1A2:

  • Fluvoxamine is an SSRI that is a strong CYP1A2 inhibitor.[ref]
  • Ciprofloxacin (antibiotic), methoxsalen, and oral contraceptives are considered moderate CYP1A2 inhibitors.[ref]

If you take an inhibitor supplement along with drinking a caffeinated drink, you may find that the effects of caffeine last longer.

CYP1A2 Gene: Ultrarapid metabolizers vs. decreased activity

In looking at CYP1A2, there are several polymorphisms, or SNPs, that either increase the activity or decrease the activity of this enzyme.

People who have the A/A genotype for rs762551 are rapid or ultrarapid metabolizers. This means that they will break down or metabolize substances such as caffeine more rapidly. Caffeine is cleared out more quickly and does not affect an ultrarapid metabolizer for as long. Unsurprisingly, ultrarapid metabolizers also tend to drink more coffee, on average.[ref]

The rs762551 C/C genotype is linked to decreased CYP1A2 enzyme activity. People with this genotype will break down caffeine more slowly and may find that it bothers their sleep at night. You’ll see your genotypes below in the genotype report section.

What are the symptoms of slow or fast CYP1A2?

Well, it depends on what substance you are breaking down.

For example, CYP 1A2 metabolizes some pro-carcinogens from tobacco smoke into carcinogens. It also helps to turn aflatoxins (molds found in grains) into active compounds involved in liver cancer. Once CYP1A2 converts the original substance into the carcinogenic metabolite, the body must eliminate it. Genetic variants can also impact how quickly the second phase of detoxification works.

Thus, the rate at which CYP1A2 metabolizes certain toxins affects the risk of certain cancers in conjunction with how well Phase II detoxification moves out the metabolites.

A slow or reduced function isn’t always bad. For example, slow or inactive CYP1A2 is thought to decrease the risk of liver toxicity from aflatoxin B.[ref] This is because CYP1A2 turns the pro-carcinogenic molecules into carcinogens, which then have to be removed from the body.

Viral infections, Covid, and inflammation decrease CYP1A2:

Acute inflammation can decrease the production of CYP enzymes. This could be important in the way that the body metabolizes medications during an infection. Studies show that acutely elevated inflammatory cytokines can dramatically reduce CYP1A2 levels.[ref]

Viral infections can also alter CYP enzyme levels. Studies show that CYP1A2 enzyme activity is decreased by over 50% during a SARS-CoV-2 infection.[ref]

If you are on a medication that is metabolized using the CYP1A2 enzyme, you may find that a viral infection or acute inflammation will alter your response to medications. For example, there are reports of toxicity for clozapine and theophylline after the onset of respiratory infections.[ref]


CYP1A2 Genotype report:

One of the interesting things to find out about your CYP1A2 genes is whether you are a fast or slow metabolizer of caffeine. This first SNP (polymorphism) is very well studied for the speed of caffeine metabolism.

CYP1A2
rs762551   (↗️ dbSNP)
AAFast or rapid metabolizer of caffeine, increased CYP1A2 activityyour genotype
ACIntermediate caffeine metabolizer; reduced risk of breast cancer in BRCA1 carriers who drink coffee; reduced risk of breast cancer in Caucasian women; reduced risk of dementia in coffee drinkersyour genotype
CCSlow caffeine metabolizer, lower CYP1A2 activity; reduced risk of breast cancer in BRCA1 mutation carriers who drink coffee; reduced risk of breast cancer in Caucasian women; reduced risk of dementia in coffee drinkersyour genotype

Your genotype for rs762551 is — (not in your raw data).

Research & references
    CYP1A2
    rs12720461   (↗️ dbSNP)
    CCtypicalyour genotype
    CTdecreased activity (carrier of one CYP1A2*1K allele)your genotype
    TTdecreased activity (CYP1A2*1K )your genotype

    Your genotype for rs12720461 is — (not in your raw data).

    Research & references
      CYP1A2
      rs72547517   (↗️ dbSNP)
      GGtypicalyour genotype
      AGdecreased activity (carrier of one CYP1A2*8 allele)your genotype
      AAdecreased activity or inactive (CYP1A2*8)your genotype

      Your genotype for rs72547517 is — (not in your raw data).

      Research & references
        CYP1A2
        rs72547515   (↗️ dbSNP)
        GGtypicalyour genotype
        AGdecreased activity (carrier of one CYP1A2*16 allele)your genotype
        AAdecreased activity or inactive (CYP1A2*16)your genotype

        Your genotype for rs72547515 is — (not in your raw data).

        Research & references

          🖨 Printable Overview (Members)

          [/mepr-show]


          Lifehacks for CYP1A2

          Your genetic variants are estimated to determine about 75% of your CYP1A2 enzyme activity, with food, supplements, and smoking impacting about 25% of the enzyme activity level.[ref]

          Thus, if you are taking a drug, such as clozapine, that is metabolized by CYP1A2, you should look at both your genes and interactions with smoking, especially if combining that with a supplement that decreases CYP1A2 activity.

          Which drugs are metabolized by CYP1A2?

          Drugs that are metabolized by CYP1A2 include: [ref][ref]

          • caffeine
          • clozapine
          • fluvoxamine
          • melatonin (endogenous and exogenous)
          • olanzapine
          • ramelteon
          • tacrine
          • theophylline
          • zolmitriptan

          CYP1A2 inhibitors:

          Curcumin is an inhibitor of CYP1A2 in humans and in animals. As I mentioned above, aflatoxin B is converted by CYP1A2 into a metabolite that is carcinogenic. Thus, inhibiting CYP1A2 with curcumin slows down the conversion of aflatoxin B into the carcinogen, which is helpful if you have slow phase II detoxification.

          A recent animal study found that curcumin prevented liver damage from aflatoxin B exposure. A potent carcinogen, aflatoxin B is a toxin produced by mold (Aspergillus) and is sometimes found in peanuts, corn, and other grains. Curcumin can be taken as a supplement and is also found in the spice, turmeric.

          Ciproflaxin, a commonly prescribed antibiotic, is also an inhibitor of CYP1A2.[ref]

          A commonly used antihistamine, cimetidine (brand name Tagamet), is also a CYP1A2 inhibitor.[ref]

          Keep in mind that your caffeine metabolism may be altered when taking a CYP1A2 inhibitor. In other words, if you are normally a fast metabolizer and drink coffee or tea with dinner, you may find yourself having problems sleeping if you pair caffeine with a CYP1A2 inhibitor like cimetidine, curcumin, or ciprofloxacin.

          Melatonin supplements and CYP1A2:

          The CYP1A2 enzyme is one of the enzymes that metabolizes melatonin – both the melatonin you naturally produce at night, as well as supplemental melatonin.[ref]

          If you are a slow CYP1A2 metabolizer, you may not clear out supplemental melatonin as quickly and are likely to have higher serum concentrations. Thus, if you are planning to start taking melatonin, you may want to start with a low dose. Additionally, you may find that melatonin stays in your system a bit longer. This means that you may want to limit melatonin to nights when you can get a full six hours or longer of sleep.

          Interestingly, melatonin is important in fighting off viral infections, such as Covid. So the natural decrease in CYP1A2 activity during a viral infection will boost your melatonin levels, thus helping the body fight off the infection.

          Related article: Benefits of Supplemental Melatonin and Studies on Melatonin for Covid.

          Caffeine and CYP1A2:

          Caffeine metabolism is more than 90% dependent on the CYP1A2 enzyme. (The CYP1A1 gene can take up the slack.)

          Slow caffeine metabolizer:
          If your genotype above shows CC for rs762551, you are likely a slow caffeine metabolizer, which means caffeine remains in your system longer. You may find that cutting off caffeine consumption at an earlier time – e.g. only having it in the morning – may help with sleep quality and sleep maintenance at night.

          But what about the AC genotype?

          Access this content:

          An active subscription is required to access this content.

          Join as a member



          Related Articles and Topics:

          Phase I and Phase II Detoxification Pathways Explained

          CYP2D6: Medication Interactions, Natural Inhibitors, and Anxiety Traits

          ABCC11 Gene: Ear wax and no body odor


          References: 

          Augustin, Marc, et al. “Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism.” The Journal of Clinical Psychiatry, vol. 79, no. 5, Sept. 2018, p. 17m12086. PubMed, https://doi.org/10.4088/JCP.17m12086.
          “ClinPGx.” ClinPGx, https://www.clinpgx.org/gene/PA27093/summaryAnnotation. Accessed 28 Jan. 2026.
          “CYP1A2.” Wikipedia, 23 Jan. 2026. Wikipedia, https://en.wikipedia.org/w/index.php?title=CYP1A2&oldid=1334467172.
          de Jong, Laura M., et al. “Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics.” Genes, vol. 11, no. 12, Dec. 2020, p. 1509. PubMed Central, https://doi.org/10.3390/genes11121509.
          Dostalek, Miroslav, et al. “The Effect of St John’s Wort (Hypericum Perforatum) on Cytochrome P450 1a2 Activity in Perfused Rat Liver.” Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, vol. 155, no. 3, Sept. 2011, pp. 253–57. PubMed, https://doi.org/10.5507/bp.2011.047.
          Eagles, Shane K., et al. “The Effects of Cruciferous Vegetable-Enriched Diets on Drug Metabolism: A Systematic Review and Meta-Analysis of Dietary Intervention Trials in Humans.” Clinical Pharmacology and Therapeutics, vol. 108, no. 2, Aug. 2020, pp. 212–27. PubMed, https://doi.org/10.1002/cpt.1811.
          Esteves, Francisco, et al. “Single Mutations in Cytochrome P450 Oxidoreductase Can Alter the Specificity of Human Cytochrome P450 1A2-Mediated Caffeine Metabolism.” Biomolecules, vol. 13, no. 7, July 2023, p. 1083. PubMed Central, https://doi.org/10.3390/biom13071083.
          Fasullo, Michael, et al. “Activation of Aflatoxin B1 by Expression of Human CYP1A2 Polymorphisms in Saccharomyces Cerevisiae.” Mutation Research. Genetic Toxicology and Environmental Mutagenesis, vol. 761, Feb. 2014, pp. 18–26. PubMed Central, https://doi.org/10.1016/j.mrgentox.2014.01.009.
          FCCP, John R. Horn, PharmD, and Philip D. Hansten PharmD. Get to Know an Enzyme: CYP1A2 | Pharmacy Times. 28 Jan. 2026, https://www.pharmacytimes.com/view/2007-11-8279.
          Fekete, Ferenc, et al. “CYP1A2 Expression Rather than Genotype Is Associated with Olanzapine Concentration in Psychiatric Patients.” Scientific Reports, vol. 13, Oct. 2023, p. 18507. PubMed Central, https://doi.org/10.1038/s41598-023-45752-6.
          Ganzera, M., et al. “Inhibitory Effects of the Essential Oil of Chamomile (Matricaria Recutita L.) and Its Major Constituents on Human Cytochrome P450 Enzymes.” Life Sciences, vol. 78, no. 8, Jan. 2006, pp. 856–61. PubMed, https://doi.org/10.1016/j.lfs.2005.05.095.
          Healy, D P, et al. “Interaction between Oral Ciprofloxacin and Caffeine in Normal Volunteers.” Antimicrobial Agents and Chemotherapy, vol. 33, no. 4, Apr. 1989, pp. 474–78. PubMed Central, https://doi.org/10.1128/aac.33.4.474.
          Lenoir, Camille, et al. “Impact of SARS‐CoV‐2 Infection (COVID‐19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail.” Clinical Pharmacology and Therapeutics, vol. 110, no. 5, Nov. 2021, pp. 1358–67. PubMed Central, https://doi.org/10.1002/cpt.2412.
          Li, Yan, et al. “In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.” Journal of Clinical Pharmacology, vol. 58, no. 10, Oct. 2018, pp. 1295–304. PubMed Central, https://doi.org/10.1002/jcph.1145.
          Qin, Xuan, et al. “The Roles of Cyp1a2 and Cyp2d in Pharmacokinetic Profiles of Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine and Its Metabolites in Mice.” European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, vol. 181, Feb. 2023, p. 106358. PubMed Central, https://doi.org/10.1016/j.ejps.2022.106358.
          Rasmussen, Birgitte B., et al. “The Interindividual Differences in the 3-Demthylation of Caffeine Alias CYP1A2 Is Determined by Both Genetic and Environmental Factors.” Pharmacogenetics, vol. 12, no. 6, Aug. 2002, pp. 473–78. PubMed, https://doi.org/10.1097/00008571-200208000-00008.
          Research, Center for Drug Evaluation and. “For Healthcare Professionals | FDA’s Examples of Drugs That Interact with CYP Enzymes and Transporter Systems.” FDA, Jan. 2026. www.fda.gov, https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems.
          Rodenburg, Eline M., et al. “CYP1A2 and Coffee Intake and the Modifying Effect of Sex, Age, and Smoking.” The American Journal of Clinical Nutrition, vol. 96, no. 1, July 2012, pp. 182–87. PubMed, https://doi.org/10.3945/ajcn.111.027102.
          Thorn, Caroline F., et al. “PharmGKB Summary: Very Important Pharmacogene Information for CYP1A2.” Pharmacogenetics and Genomics, vol. 22, no. 1, Jan. 2012, pp. 73–77. PubMed Central, https://doi.org/10.1097/FPC.0b013e32834c6efd.
          Unger, Matthias, and Andreas Frank. “Simultaneous Determination of the Inhibitory Potency of Herbal Extracts on the Activity of Six Major Cytochrome P450 Enzymes Using Liquid Chromatography/Mass Spectrometry and Automated Online Extraction.” Rapid Communications in Mass Spectrometry: RCM, vol. 18, no. 19, 2004, pp. 2273–81. PubMed, https://doi.org/10.1002/rcm.1621.
          Wei, Binnian, et al. “Examining the Association between the Body Burdens of Harmful Chemicals and the Heaviness of Marijuana Smoking.” Chemical Research in Toxicology, vol. 31, no. 8, Aug. 2018, pp. 643–45. PubMed Central, https://doi.org/10.1021/acs.chemrestox.8b00160.
          Zhang, Ni-Ya, et al. “Curcumin Prevents Aflatoxin B₁ Hepatoxicity by Inhibition of Cytochrome P450 Isozymes in Chick Liver.” Toxins, vol. 8, no. 11, Nov. 2016, p. 327. PubMed, https://doi.org/10.3390/toxins8110327.

          About the Author:
          Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.